Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Disulfiram is a small molecule drug primarily used to support the treatment of chronic alcoholism by producing an acute sensitivity to ethanol. It acts as an irreversible inhibitor of the enzyme acetaldehyde dehydrogenase (ALDH), leading to accumulation of acetaldehyde when alcohol is consumed. This results in unpleasant physiological reactions such as flushing, tachycardia, hypotension, nausea, vomiting, and headache within minutes after alcohol intake. The deterrent effect helps discourage alcohol consumption[1][4][5]. Disulfiram does not reduce cravings for alcohol but relies on aversive conditioning. It is typically administered orally in tablet form and its effects can persist for up to two weeks after discontinuation due to slow elimination from the body[2][4].\nBeyond its approved use in alcohol dependence therapy, research has explored potential applications in cancer therapy (notably via inhibition of NPL4-p97 complex), parasitic infections, and latent HIV infection[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on disulfiram.